Outcomes by sex following treatment initiation with darunavir/cobicistat in a large Spanish cohort of the CODAR study (GeSIDA 9316)

Autor: Perez Elias, MJ, Alejos, B, Vivancos, MJ, Ribera, E, Galindo, MJ, Vilanova-Trillo, L, Fraile, LJGF, Moral, SDL, De Lomas, JG, Lozano, F, Garcia, MGM, Pitarch, MT, Martinez, MD, Rojas, J, Raya-Cruz, M, Sepulveda, MA, Troya, J, Del Campo, S, Martinez, E, Callau, P, Moreno, A, Casado, JL, Sanchez, JM, Ayerbe, CG, Negredo, E, Campos, I, Puig, J, Torrella, A, Planas, B, Knobel, H, Ferrando, R, Crespo, M, Ocampo, A, Sanz, J, de Los Santos, I, Diaz, A, Carbonero, LM, de la Torre, J, Reina, MR, Santos, J, Maria, C, Domenech, G, Gutierrez, MM, Montero, M, Cuellar, S, Boix, V, Payeras, A, Ryan, P, Torralba, M, Cuadra, F, Aznar, E, Esteban, H, de Miguel, M, Gonzalez, P, Yllescas, M

Publikováno v: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Background Few women have been included in darunavir/cobicistat clinical development studies, and hardly any of them were antiretroviral experienced or treated with anything other than triple-based therapies. Objectives Our aim was to increase our kn

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::6906439be0e154ba4ffa352f2292be69
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2404

Rate of hepatitis C reinfection after successful direct-acting antivirals treatment among people who inject drugs in Spain: the LIVERate study.

Autor: Chacón F; Merck Sharp and Dohme, Madrid, Spain. fernando.chacon3@merck.com., Morano L; Álvaro Cunqueiro University Hospital, Vigo, Spain., Navarro J; Vall d'Hebron University Hospital, Barcelona, Spain., Granados R; Doctor Negrín University Hospital of Gran Canaria, Las Palmas de Gran Canaria, Spain., Llibre JM; Germans Trias i Pujol Hospital, Badalona, Spain., Ryan P; Infanta Leonor University Hospital, Madrid, Spain.; Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.; Complutense University, Madrid, Spain.; Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain., Aldámiz-Echevarria T; Gregorio Marañón University Hospital, Madrid, Spain., Carbonero LM; La Paz University Hospital, Madrid, Spain., Puigvehí M; del Mar Hospital, Barcelona, Spain., Clotet-Codina I; Merck Sharp and Dohme, Madrid, Spain., Sanchez-Vega N; Merck Sharp and Dohme, Madrid, Spain., Vacas E; Merck Sharp and Dohme, Madrid, Spain., Rincón O; Merck Sharp and Dohme, Madrid, Spain., Berenguer J; Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain., Crespo J; Marqués de Valdecilla University Hospital, Santander, Spain., Roncero C; Health Science Faculty, European University Miguel de Cervantes, Valladolid, Spain.

Publikováno v: BMC public health [BMC Public Health] 2024 Nov 14; Vol. 24 (1), pp. 3167. Date of Electronic Publication: 2024 Nov 14.